Search

Search Constraints

You searched for: Author/Creator Hibi, T

Search Results

1. OP38 Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis. (25th January 2019)

2. DOP32 Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). (25th January 2019)

5. DOP46 Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial. (25th January 2019)

7. DOP056 Efficacy and safety of anti-fractalkine monoclonal antibody, E6011, in patients with Crohn's disease who had lost response to anti-TNFα agents: A multicentre, open-label, Phase 1/2 study. (16th January 2018)

10. Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Issue 3 (20th September 2005)